Why the study?
Do advanced risk stratification methods (CMR, T-wave alternans, genetic testing) improve the selection of patients with dilated cardiomyopathy for implantable cardioverter-defibrillators compared to left ventricular ejection fraction alone?
Do advanced risk stratification methods (CMR, T-wave alternans, genetic testing) improve the selection of patients with dilated cardiomyopathy for implantable cardioverter-defibrillators compared to left ventricular ejection fraction alone?
Advanced risk stratification techniques like CMR for myocardial fibrosis, microvolt T-wave alternans, and genetic testing hold promise for better identifying DCM patients who will benefit from ICDs.
No takes yet. Share an insight, caveat, or question.
May support refined SCD risk assessment in DCM; leaves open whether this improves ICD selection pending prospective trials.
Halliday et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: